Literature DB >> 24464841

Inhibitory activities of trichostatin a in U87 glioblastoma cells and tumorsphere-derived cells.

Felipe de Almeida Sassi1, Lílian Caesar, Mariane Jaeger, Carolina Nör, Ana Lucia Abujamra, Gilberto Schwartsmann, Caroline Brunetto de Farias, Algemir Lunardi Brunetto, Patrícia Luciana da Costa Lopez, Rafael Roesler.   

Abstract

Epigenetic alterations have been increasingly implicated in glioblastoma (GBM) pathogenesis, and epigenetic modulators including histone deacetylase inhibitors (HDACis) have been investigated as candidate therapies. GBMs are proposed to contain a subpopulation of glioblastoma stem cells (GSCs) that sustain tumor progression and therapeutic resistance and can form tumorspheres in culture. Here, we investigate the effects of the HDACi trichostatin A (TSA) in U87 GBM cultures and tumorsphere-derived cells. Using approaches that include a novel method to measure tumorsphere sizes and the area covered by spheres in GBM cultures, as well as a nuclear morphometric analysis, we show that TSA reduced proliferation and colony sizes, led to G2/M arrest, induced alterations in nuclear morphology consistent with cell senescence, and increased the protein content of GFAP, but did not affect migration, in cultured human U87 GBM cells. In cells expanded in tumorsphere assays, TSA reduced sphere formation and induced neuron-like morphological changes. The expression of stemness markers in these cells was detected by reverse transcriptase polymerase chain reaction. These findings indicate that HDACis can inhibit proliferation, survival, and tumorsphere formation, and promote differentiation of U87 GBM cells, providing further evidence for the development of HDACis as potential therapeutics against GBM.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24464841     DOI: 10.1007/s12031-014-0241-7

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  80 in total

1.  Different effects of histone deacetylase inhibitors nicotinamide and trichostatin A (TSA) in C17.2 neural stem cells.

Authors:  Haifeng Wang; Hua Cheng; Kai Wang; Tieqiao Wen
Journal:  J Neural Transm (Vienna)       Date:  2012-03-13       Impact factor: 3.575

Review 2.  Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?

Authors:  Ricky W Johnstone; Jonathan D Licht
Journal:  Cancer Cell       Date:  2003-07       Impact factor: 31.743

3.  Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP.

Authors:  A Bangert; S Cristofanon; I Eckhardt; B A Abhari; S Kolodziej; S Häcker; S H K Vellanki; J Lausen; K-M Debatin; S Fulda
Journal:  Oncogene       Date:  2012-01-23       Impact factor: 9.867

4.  Spheres without influence: dissociating in vitro self-renewal from tumorigenic potential in glioma.

Authors:  Tracy-Ann Read; Robert J Wechsler-Reya
Journal:  Cancer Cell       Date:  2012-01-17       Impact factor: 31.743

5.  Eyes wide open: a critical review of sphere-formation as an assay for stem cells.

Authors:  Erika Pastrana; Violeta Silva-Vargas; Fiona Doetsch
Journal:  Cell Stem Cell       Date:  2011-05-06       Impact factor: 24.633

6.  Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors.

Authors:  Thomas Asklund; Samuel Kvarnbrink; Camilla Holmlund; Carl Wibom; Tommy Bergenheim; Roger Henriksson; Håkan Hedman
Journal:  Anticancer Res       Date:  2012-07       Impact factor: 2.480

7.  Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.

Authors:  Dominik Sturm; Hendrik Witt; Volker Hovestadt; Dong-Anh Khuong-Quang; David T W Jones; Carolin Konermann; Elke Pfaff; Martje Tönjes; Martin Sill; Sebastian Bender; Marcel Kool; Marc Zapatka; Natalia Becker; Manuela Zucknick; Thomas Hielscher; Xiao-Yang Liu; Adam M Fontebasso; Marina Ryzhova; Steffen Albrecht; Karine Jacob; Marietta Wolter; Martin Ebinger; Martin U Schuhmann; Timothy van Meter; Michael C Frühwald; Holger Hauch; Arnulf Pekrun; Bernhard Radlwimmer; Tim Niehues; Gregor von Komorowski; Matthias Dürken; Andreas E Kulozik; Jenny Madden; Andrew Donson; Nicholas K Foreman; Rachid Drissi; Maryam Fouladi; Wolfram Scheurlen; Andreas von Deimling; Camelia Monoranu; Wolfgang Roggendorf; Christel Herold-Mende; Andreas Unterberg; Christof M Kramm; Jörg Felsberg; Christian Hartmann; Benedikt Wiestler; Wolfgang Wick; Till Milde; Olaf Witt; Anders M Lindroth; Jeremy Schwartzentruber; Damien Faury; Adam Fleming; Magdalena Zakrzewska; Pawel P Liberski; Krzysztof Zakrzewski; Peter Hauser; Miklos Garami; Almos Klekner; Laszlo Bognar; Sorana Morrissy; Florence Cavalli; Michael D Taylor; Peter van Sluis; Jan Koster; Rogier Versteeg; Richard Volckmann; Tom Mikkelsen; Kenneth Aldape; Guido Reifenberger; V Peter Collins; Jacek Majewski; Andrey Korshunov; Peter Lichter; Christoph Plass; Nada Jabado; Stefan M Pfister
Journal:  Cancer Cell       Date:  2012-10-16       Impact factor: 31.743

8.  The histone deacetylase inhibitor trichostatin a promotes apoptosis and antitumor immunity in glioblastoma cells.

Authors:  Elisabeth Höring; Oliver Podlech; Björn Silkenstedt; Ioanna Alexandros Rota; Eleni Adamopoulou; Ulrike Naumann
Journal:  Anticancer Res       Date:  2013-04       Impact factor: 2.480

9.  The histone deacetylase inhibitor sodium butyrate promotes cell death and differentiation and reduces neurosphere formation in human medulloblastoma cells.

Authors:  Carolina Nör; Felipe A Sassi; Caroline Brunetto de Farias; Gilberto Schwartsmann; Ana Lucia Abujamra; Guido Lenz; Algemir Lunardi Brunetto; Rafael Roesler
Journal:  Mol Neurobiol       Date:  2013-03-21       Impact factor: 5.590

10.  Beyond Genetics in Glioma Pathways: The Ever-Increasing Crosstalk between Epigenomic and Genomic Events.

Authors:  Ramón Martínez
Journal:  J Signal Transduct       Date:  2012-06-18
View more
  9 in total

1.  Combined Inhibition of HDAC and EGFR Reduces Viability and Proliferation and Enhances STAT3 mRNA Expression in Glioblastoma Cells.

Authors:  Marienela Buendia Duque; Kelly de Vargas Pinheiro; Amanda Thomaz; Camila Alves da Silva; Natália Hogetop Freire; André Tesainer Brunetto; Gilberto Schwartsmann; Mariane Jaeger; Caroline Brunetto de Farias; Rafael Roesler
Journal:  J Mol Neurosci       Date:  2019-03-18       Impact factor: 3.444

2.  Combinatorial therapy with acetylation and methylation modifiers attenuates lung vascular hyperpermeability in endotoxemia-induced mouse inflammatory lung injury.

Authors:  Jayakumar Thangavel; Asrar B Malik; Harold K Elias; Sheeja Rajasingh; Andrew D Simpson; Premanand K Sundivakkam; Stephen M Vogel; Yu-Ting Xuan; Buddhadeb Dawn; Johnson Rajasingh
Journal:  Am J Pathol       Date:  2014-06-12       Impact factor: 4.307

3.  Inhibition of histone deacetylases sensitizes glioblastoma cells to lomustine.

Authors:  Mikkel Staberg; Signe Regner Michaelsen; Rikke Darling Rasmussen; Mette Villingshøj; Hans Skovgaard Poulsen; Petra Hamerlik
Journal:  Cell Oncol (Dordr)       Date:  2016-10-20       Impact factor: 6.730

4.  Epigenetic modifiers reduce inflammation and modulate macrophage phenotype during endotoxemia-induced acute lung injury.

Authors:  Jayakumar Thangavel; Saheli Samanta; Sheeja Rajasingh; Bahar Barani; Yu-Ting Xuan; Buddhadeb Dawn; Johnson Rajasingh
Journal:  J Cell Sci       Date:  2015-06-26       Impact factor: 5.285

5.  Spheres from cervical cancer cells display stemness and cancer drug resistance.

Authors:  Huan Liu; Haijuan Wang; Chunxiao Li; Tingting Zhang; Xiting Meng; Ying Zhang; Haili Qian
Journal:  Oncol Lett       Date:  2016-07-20       Impact factor: 2.967

6.  Combination Therapy with Sulfasalazine and Valproic Acid Promotes Human Glioblastoma Cell Death Through Imbalance of the Intracellular Oxidative Response.

Authors:  Carlos Gustavo Garcia; Suzana Assad Kahn; Luiz Henrique Medeiros Geraldo; Igor Romano; Ivan Domith; Deborah Christinne Lima E Silva; Fernando Dos Santos Assunção; Marcos José Ferreira; Camila Cabral Portugal; Jorge Marcondes de Souza; Luciana Ferreira Romão; Annibal Duarte Pereira Netto; Flávia Regina Souza Lima; Marcelo Cossenza
Journal:  Mol Neurobiol       Date:  2018-01-19       Impact factor: 5.590

Review 7.  Molecular Mechanisms of Vascular Damage During Lung Injury.

Authors:  Ramon Bossardi Ramos; Alejandro Pablo Adam
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

8.  RNAi for contactin 2 inhibits proliferation of U87-glioma stem cells by downregulating AICD, EGFR, and HES1.

Authors:  Yang Guo; Peidong Zhang; Hongtian Zhang; Peng Zhang; Ruxiang Xu
Journal:  Onco Targets Ther       Date:  2017-02-13       Impact factor: 4.147

9.  Molecular imaging HDACs class IIa expression-activity and pharmacologic inhibition in intracerebral glioma models in rats using PET/CT/(MRI) with [18F]TFAHA.

Authors:  Maxwell T Laws; Robin E Bonomi; Swatabdi Kamal; David J Gelovani; Jeremy Llaniguez; Shreya Potukutchi; Xin Lu; Thomas Mangner; Juri G Gelovani
Journal:  Sci Rep       Date:  2019-03-05       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.